Sequences tumor samples in certified labs and uses the results to train AI that recommends cancer treatments.
At a glance
- Depends onMidstream position: 4 outgoing, 6 incoming connections
- Scale
Sequences tumor samples in certified labs and uses the results to train AI that recommends cancer treatments.
What this company is and how it runs — written from structure, not news.
Tempus AI runs federally certified laboratories that sequence tumor samples and feeds those molecular profiles into FDA-cleared machine learning algorithms, producing treatment recommendations for oncologists. Because the same patient sample that generates a diagnostic result also produces a new training record for the algorithm, the laboratory and the AI platform are not two separate products but one continuous loop — each test makes the next prediction more accurate at no added cost. Health systems wire the AI outputs directly into their EHR software and oncologists learn to read Tempus-specific report formats, so switching platforms would mean rebuilding clinical integrations and retraining staff at the same time pharmaceutical partners would have to renegotiate trial protocols built around Tempus biomarker panels. The loop's strength is also its fragility: because neither the laboratory nor the AI platform can function as a diagnostic product without the other, an FDA enforcement action against the software alone would suspend the outcomes-ingestion feed, degrade model accuracy, and strip the sequencing results of the clinical context that health systems contracted for.
How does this company make money?
The company charges a fee for each genomic sequencing test, billed to the patient's insurance or directly to the patient. Health systems and pharmaceutical companies also pay subscription fees for ongoing access to the AI platform. On top of that, pharmaceutical companies pay project-based contracts for drug development work — finding biomarkers that predict which patients will respond to a drug, and supporting the clinical trials those companies run.
What makes this company hard to replace?
Health systems sign multi-year contracts and build custom integrations that wire the AI outputs directly into their EHR software, so removing the platform would require rebuilding those integrations from scratch. Oncologists learn to read and act on this company's specific genomic report formats and recommendation structures, and switching to a different format means retraining clinical staff. Pharmaceutical partners write their clinical trial protocols around this company's specific biomarker panels and data formats, and migrating those protocols to a new platform would require renegotiating trial design with regulators.
What limits this company?
Opening a new laboratory in a new city requires a separate federal CLIA certification and a separate license from each state before a single patient sample can be touched. No amount of money or equipment shortens that filing process, so the speed of geographic growth is set entirely by how fast regulators approve each new location.
What does this company depend on?
The company cannot operate without CLIA-certified laboratory facilities to process physical samples, FDA 510(k) clearances to legally deploy the AI as a medical device, Illumina sequencing platforms to read the molecular profiles, Epic and other EHR systems to collect real-world patient outcomes, and ongoing clinical partnerships with health systems to keep that outcomes data flowing.
Who depends on this company?
Oncologists at partner health systems rely on the AI-generated treatment recommendations and molecular profiles to make precision therapy decisions — without them, those physicians lose the genomic guidance embedded in their daily workflows. Pharmaceutical companies running clinical trials depend on the company's genomically characterized patient cohorts and real-world evidence datasets for biomarker discovery and the regulatory submissions they file with the FDA.
How does this company scale?
The machine learning algorithms get more accurate as more patient outcome data flows through the platform, so each new patient passively strengthens the product for every future patient at no additional cost. What does not scale cheaply is the physical side: every new laboratory requires specialized technicians, physical infrastructure, and a fresh round of regulatory compliance filings that cannot be automated or done remotely.
What external forces can significantly affect this company?
FDA medical device regulations can delay new product launches by years and require continuous quality system compliance, so any change to the AI software triggers a formal review process. Medicare reimbursement policy directly controls how much can be charged per test and how often oncologists order them, meaning a policy change can shrink revenue without any action by the company. HIPAA privacy rules limit how patient data can be combined across different health systems, which constrains how quickly the AI training dataset can grow.
Where is this company structurally vulnerable?
If the FDA took enforcement action against the AI software — because of a quality-system failure or an algorithm update that was not properly validated — the AI platform would be suspended. Without it, the laboratory's sequencing results would no longer feed into treatment recommendations, the outcomes data would stop flowing, and the model would start degrading. Health systems and pharmaceutical partners whose workflows are built around the AI outputs would immediately lose the thing they integrated for.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Three price-behavior observations have aligned: the ulcer index (drawdown depth and duration composite) is elevated, current drawdown from peak is significant, and 20-week annualized volatility is in the upper portion of its mapped range.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph